NO328775B1 - Komprimerte tabletter omfattende valsartan. - Google Patents

Komprimerte tabletter omfattende valsartan. Download PDF

Info

Publication number: NO328775B1
Authority: NO; Norway
Prior art keywords: receptor; valsartan; lung; ati; receptors
Prior art date: 1998-12-23

Application number

NO20013143A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013143D0 (no

NO20013143L (no

Inventor

Marc De Gasparo

Gillian Rosemary Bullock

Sabina Maria Ganter

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-23

Filing date

2001-06-22

Publication date

2010-05-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO328775(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-12-23 Priority claimed from EP98811258A external-priority patent/EP1013273A1/en

2001-06-22 Application filed by Novartis Ag filed Critical Novartis Ag

2001-06-22 Publication of NO20013143D0 publication Critical patent/NO20013143D0/no

2001-08-16 Publication of NO20013143L publication Critical patent/NO20013143L/no

2010-05-10 Publication of NO328775B1 publication Critical patent/NO328775B1/no

Links

239000004072 C09CA03 - Valsartan Substances 0.000 title claims description 29
229960004699 valsartan Drugs 0.000 title claims description 28
239000007891 compressed tablet Substances 0.000 title claims description 21
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title claims 8
239000003826 tablet Substances 0.000 claims description 26
239000007941 film coated tablet Substances 0.000 claims description 14
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 13
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
229960000913 crospovidone Drugs 0.000 claims description 11
239000008108 microcrystalline cellulose Substances 0.000 claims description 11
229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 11
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 11
239000013543 active substance Substances 0.000 claims description 8
239000008358 core component Substances 0.000 claims description 3
201000010099 disease Diseases 0.000 abstract description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
150000003839 salts Chemical class 0.000 abstract description 8
239000002333 angiotensin II receptor antagonist Substances 0.000 abstract description 5
229940075993 receptor modulator Drugs 0.000 abstract description 4
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 abstract description 2
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
102000005962 receptors Human genes 0.000 description 41
108020003175 receptors Proteins 0.000 description 41
101150116411 AGTR2 gene Proteins 0.000 description 34
210000004072 lung Anatomy 0.000 description 32
239000000203 mixture Substances 0.000 description 29
238000009826 distribution Methods 0.000 description 27
238000000034 method Methods 0.000 description 27
210000001519 tissue Anatomy 0.000 description 24
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 20
238000007906 compression Methods 0.000 description 18
230000006835 compression Effects 0.000 description 16
238000009472 formulation Methods 0.000 description 16
210000004027 cell Anatomy 0.000 description 15
102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 14
210000002919 epithelial cell Anatomy 0.000 description 13
239000007787 solid Substances 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
238000010186 staining Methods 0.000 description 12
210000000981 epithelium Anatomy 0.000 description 11
238000007901 in situ hybridization Methods 0.000 description 11
230000004807 localization Effects 0.000 description 11
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 10
239000008187 granular material Substances 0.000 description 10
239000000523 sample Substances 0.000 description 10
101800000733 Angiotensin-2 Proteins 0.000 description 9
102400000345 Angiotensin-2 Human genes 0.000 description 9
210000002950 fibroblast Anatomy 0.000 description 9
238000003365 immunocytochemistry Methods 0.000 description 9
239000006186 oral dosage form Substances 0.000 description 9
210000000329 smooth muscle myocyte Anatomy 0.000 description 9
-1 1H-tetrazol-5-yl Chemical group 0.000 description 8
210000004907 gland Anatomy 0.000 description 8
239000002253 acid Substances 0.000 description 7
229950006323 angiotensin ii Drugs 0.000 description 7
210000002540 macrophage Anatomy 0.000 description 7
239000000463 material Substances 0.000 description 7
238000003752 polymerase chain reaction Methods 0.000 description 7
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
239000000654 additive Substances 0.000 description 6
210000004404 adrenal cortex Anatomy 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000002464 receptor antagonist Substances 0.000 description 6
229940044551 receptor antagonist Drugs 0.000 description 6
238000012360 testing method Methods 0.000 description 6
102000008873 Angiotensin II receptor Human genes 0.000 description 5
208000026310 Breast neoplasm Diseases 0.000 description 5
206010058467 Lung neoplasm malignant Diseases 0.000 description 5
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 5
201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
206010006451 bronchitis Diseases 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
201000005202 lung cancer Diseases 0.000 description 5
208000020816 lung neoplasm Diseases 0.000 description 5
210000000110 microvilli Anatomy 0.000 description 5
108050000824 Angiotensin II receptor Proteins 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 4
206010006458 Bronchitis chronic Diseases 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
210000001943 adrenal medulla Anatomy 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000002585 base Substances 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
208000007451 chronic bronchitis Diseases 0.000 description 4
238000000576 coating method Methods 0.000 description 4
238000010191 image analysis Methods 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
239000012188 paraffin wax Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
208000023504 respiratory system disease Diseases 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
206010016654 Fibrosis Diseases 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
230000003510 anti-fibrotic effect Effects 0.000 description 3
230000001028 anti-proliverative effect Effects 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
210000000424 bronchial epithelial cell Anatomy 0.000 description 3
239000002775 capsule Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000000306 component Substances 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
230000004761 fibrosis Effects 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
229960002003 hydrochlorothiazide Drugs 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
210000002570 interstitial cell Anatomy 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
210000003097 mucus Anatomy 0.000 description 3
239000013642 negative control Substances 0.000 description 3
230000000414 obstructive effect Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
230000000861 pro-apoptotic effect Effects 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000003827 upregulation Effects 0.000 description 3
210000003556 vascular endothelial cell Anatomy 0.000 description 3
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
101710124361 Arylamine N-acetyltransferase 2 Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
208000003241 Fat Embolism Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
206010053879 Sepsis syndrome Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000002612 cardiopulmonary effect Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000003736 gastrointestinal content Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
238000000227 grinding Methods 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
231100000516 lung damage Toxicity 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000005096 rolling process Methods 0.000 description 2
230000035939 shock Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000008733 trauma Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
101150059573 AGTR1 gene Proteins 0.000 description 1
208000017612 Acute Hemorrhagic Pancreatitis Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
102000004881 Angiotensinogen Human genes 0.000 description 1
108090001067 Angiotensinogen Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
241001440269 Cutina Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101500024730 Homo sapiens Angiotensin-2 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033650 Pancreatitis haemorrhagic Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
208000011191 Pulmonary vascular disease Diseases 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
210000001552 airway epithelial cell Anatomy 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
239000000584 angiotensin II type 2 receptor blocker Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002787 antisense oligonuctleotide Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
210000003321 cartilage cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229930002875 chlorophyll Natural products 0.000 description 1
235000019804 chlorophyll Nutrition 0.000 description 1
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
208000016356 hereditary diffuse gastric adenocarcinoma Diseases 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
208000030776 invasive breast carcinoma Diseases 0.000 description 1
206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
201000010985 invasive ductal carcinoma Diseases 0.000 description 1
206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000009607 mammography Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
208000030163 medullary breast carcinoma Diseases 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical class CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
201000011682 nervous system cancer Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
IPSIPYMEZZPCPY-UHFFFAOYSA-N new fuchsin Chemical compound [Cl-].C1=CC(=[NH2+])C(C)=CC1=C(C=1C=C(C)C(N)=CC=1)C1=CC=C(N)C(C)=C1 IPSIPYMEZZPCPY-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000003973 paint Substances 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
230000006659 positive regulation of apoptotic process Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000011164 primary particle Substances 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
239000008213 purified water Substances 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
230000036454 renin-angiotensin system Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
210000001533 respiratory mucosa Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000003537 structural cell Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20013143A 1998-12-23 2001-06-22 Komprimerte tabletter omfattende valsartan. NO328775B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98811257		1998-12-23
EP98811258A EP1013273A1 (en)	1998-12-23	1998-12-23	Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
PCT/EP1999/010330 WO2000038676A1 (en)	1998-12-23	1999-12-22	Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Publications (3)

Publication Number	Publication Date
NO20013143D0 NO20013143D0 (no)	2001-06-22
NO20013143L NO20013143L (no)	2001-08-16
NO328775B1 true NO328775B1 (no)	2010-05-10

Family

ID=26152118

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20013143A NO328775B1 (no)	1998-12-23	2001-06-22	Komprimerte tabletter omfattende valsartan.
NO20100041A NO20100041L (no)	1998-12-23	2010-01-12	Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20100041A NO20100041L (no)	1998-12-23	2010-01-12	Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer

Country Status (26)

Country	Link
EP (3)	EP1588706B1 (xx)
JP (2)	JP2002533390A (xx)
KR (1)	KR100646716B1 (xx)
CN (2)	CN1304000C (xx)
AT (2)	ATE524176T1 (xx)
AU (4)	AU3043000A (xx)
BR (1)	BR9916576A (xx)
CA (2)	CA2351357A1 (xx)
CY (2)	CY1106581T1 (xx)
CZ (2)	CZ297795B6 (xx)
DE (1)	DE69935249T2 (xx)
DK (2)	DK1140071T3 (xx)
ES (2)	ES2281978T3 (xx)
HK (1)	HK1038888B (xx)
HU (1)	HUP0104780A3 (xx)
ID (1)	ID29856A (xx)
IL (5)	IL143233A0 (xx)
NO (2)	NO328775B1 (xx)
NZ (3)	NZ587909A (xx)
PL (1)	PL199100B1 (xx)
PT (2)	PT1588706E (xx)
RU (3)	RU2271809C2 (xx)
SI (2)	SI1140071T1 (xx)
SK (1)	SK9132001A3 (xx)
TR (7)	TR200605472T1 (xx)
WO (1)	WO2000038676A1 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001097805A2 (en) *	2000-06-22	2001-12-27	Novartis Ag	Solid valsartan pharmaceutical compositions
JP4972847B2 (ja) *	2000-10-11	2012-07-11	住友化学株式会社	コラーゲン蓄積抑制剤
WO2002083127A1 (fr) *	2001-04-09	2002-10-24	Tokai University Educational System	Compositions inhibant la modification proteique
ATE372987T1 (de)	2001-05-31	2007-09-15	Vicore Pharma Ab	Trizyklische verbindungen, nützlich als angiotensin ii agonisten
US7812044B2 (en)	2001-11-13	2010-10-12	Takeda Pharmaceutical Company Limited	Anticancer agents
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
PL382044A1 (pl) *	2003-11-03	2007-08-06	Zentiva, A.S.	Preparat zawierający walsartan
SI2033629T1 (sl)	2004-12-24	2013-01-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Trden farmacevtski sestavek, ki obsega valsartan
EP2650011A1 (en) *	2004-12-24	2013-10-16	Spinifex Pharmaceuticals Pty Ltd	Method of treatment or prophylaxis
WO2006136916A2 (en) *	2005-06-20	2006-12-28	Glenmark Pharmaceuticals Limited	Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (es)	2005-08-17	2007-03-21		Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
ES2246742B1 (es) *	2005-09-06	2007-02-01	Prous Institute For Biomedical Research S.A.	Uso de un derivado de imidazol.
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
US20110027358A1 (en) *	2007-03-29	2011-02-03	Rajesh Kshirsagar	Valsartan tablet formulations
TR200703568A1 (tr)	2007-05-24	2008-07-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Valsartan formülasyonları
JP2011500577A (ja)	2007-10-09	2011-01-06	ノバルティスアーゲー	バルサルタンの医薬製剤
EP2217205B1 (en) *	2007-11-06	2015-03-04	Novartis AG	Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
US20110104166A1 (en) *	2008-01-18	2011-05-05	Stankovic Konstantina M	Methods and Compositions for Treating Polyps
GB0802931D0 (en) *	2008-02-18	2008-03-26	Queen Mary & Westfield College	Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
EP2405899A2 (en)	2009-03-11	2012-01-18	Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi	Valsartan formulations
EP2536396B1 (en)	2010-02-16	2016-08-10	KRKA, D.D., Novo Mesto	Process for the preparation of oral solid dosage forms comprising valsartan
EP2455388A1 (en)	2010-11-23	2012-05-23	LanthioPep B.V.	Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN102266307B (zh) *	2011-08-01	2012-10-24	海南锦瑞制药股份有限公司	一种缬沙坦胶囊及其制备方法
WO2013098578A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan
EA018867B1 (ru) *	2012-11-01	2013-11-29	Лаборатория Тютор С.А.С.И.Ф.И.А.	Способ получения фармацевтической композиции и продукт способа
CN114514032A (zh)	2019-08-02	2022-05-17	兰提欧派普有限公司	用于治疗癌症的血管紧张素2型(at2)受体激动剂
EP4295839A1 (en)	2022-06-20	2023-12-27	KRKA, d.d., Novo mesto	Combination of valsartan and indapamide
WO2024026528A1 (en) *	2022-08-02	2024-02-08	Dimerix Bioscience Pty Ltd	Dosage regimen for the treatment of copd

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3146168A (en)	1962-04-10	1964-08-25	Fmc Corp	Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en)	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
EP0330284B1 (en) *	1988-02-25	1994-07-27	Yamanouchi Europe B.V.	Process for the preparation of a pharmaceutical granulate
EP0955294B1 (en)	1989-06-14	2003-09-24	Smithkline Beecham Corporation	Imidazolyl-alkenoic acid
IE70593B1 (en)	1989-09-29	1996-12-11	Eisai Co Ltd	Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0443983B1 (de) *	1990-02-19	1996-02-28	Ciba-Geigy Ag	Acylverbindungen
NZ237476A (en)	1990-03-20	1994-01-26	Sanofi Sa	N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en)	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en)	1990-09-10	1992-03-11	Abbott Lab	Angiotensin ii receptor antagonists
WO1992005784A1 (en) *	1990-10-02	1992-04-16	Warner-Lambert Company	4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
DE4038335A1 (de) *	1990-12-01	1992-06-04	Boehringer Mannheim Gmbh	Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
SI9210098B (sl) *	1991-02-06	2000-06-30	Dr. Karl Thomae	Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5591762A (en) *	1991-02-06	1997-01-07	Dr. Karl Thomae Gmbh	Benzimidazoles useful as angiotensin-11 antagonists
US5196537A (en)	1991-03-21	1993-03-23	G. D. Searle & Co.	5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en)	1991-05-16	1991-07-03	Glaxo Group Ltd	Chemical compounds
DE4132632A1 (de) *	1991-10-01	1993-04-08	Bayer Ag	Substituierte imidazolyl-propensaeurederivate
DE4309968A1 (de) *	1993-03-26	1994-09-29	Bayer Ag	Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten
NZ251741A (en)	1992-04-13	1997-06-24	Zeneca Ltd	Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity
EP0673369A1 (de) *	1992-12-11	1995-09-27	Novartis AG	Substituierte benzazepinone
HUT72330A (en)	1992-12-11	1996-04-29	Ciba Geigy Ag	Substituted benzoxazepinone derivatives, process for producing them and pharmaceutical compositions containing them
DE4309963A1 (de) *	1993-03-26	1994-09-29	Hubert Kamperschroer	Faß zum Austragen von Gülle
FR2716882B1 (fr) *	1994-03-04	1996-04-05	Roussel Uclaf	Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4408497A1 (de) *	1994-03-14	1995-09-21	Thomae Gmbh Dr K	Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
HUT76542A (en)	1994-03-17	1997-09-29	Ciba Geigy Ag	Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
DE4432860A1 (de) *	1994-09-15	1996-03-21	Merck Patent Gmbh	Imidazopyridine
US6071931A (en)	1995-10-06	2000-06-06	Novartis Ag	AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
AU2316997A (en)	1996-02-27	1997-09-16	David H Thompson	Liposomal delivery system
ES2189940T3 (es) *	1996-02-29	2003-07-16	Novartis Ag	Antagonista de receptor at1 para la estimulacion de la apoptosis.
GB9613470D0 (en)	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
DE19628617A1 (de) *	1996-07-16	1998-01-22	Basf Ag	Direkttablettierhilfsmittel
KR100550167B1 (ko)	1998-07-10	2006-02-08	노파르티스 아게	발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
CA2360691A1 (en) *	1999-01-26	2000-08-03	Novartis Ag	Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
WO2001097805A2 (en) *	2000-06-22	2001-12-27	Novartis Ag	Solid valsartan pharmaceutical compositions
WO2005039637A2 (en)	2003-10-17	2005-05-06	Novartis Ag	Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
JP2009018990A (ja)	2005-10-25	2009-01-29	Univ Kurume	Ｃ型肝炎ウイルス由来ペプチド

1999
- 1999-12-22 NZ NZ587909A patent/NZ587909A/en not_active IP Right Cessation
- 1999-12-22 EP EP05013209A patent/EP1588706B1/en not_active Revoked
- 1999-12-22 TR TR2006/05472T patent/TR200605472T1/xx unknown
- 1999-12-22 CN CNB998150452A patent/CN1304000C/zh not_active Expired - Fee Related
- 1999-12-22 TR TR2001/01784T patent/TR200101784T2/xx unknown
- 1999-12-22 AU AU30430/00A patent/AU3043000A/en not_active Abandoned
- 1999-12-22 PT PT05013209T patent/PT1588706E/pt unknown
- 1999-12-22 DK DK99964665T patent/DK1140071T3/da active
- 1999-12-22 CN CNA200410087973XA patent/CN1636561A/zh active Pending
- 1999-12-22 ID IDW00200101299Q patent/ID29856A/id unknown
- 1999-12-22 AT AT05013209T patent/ATE524176T1/de active
- 1999-12-22 TR TR2002/00764T patent/TR200200764T2/xx unknown
- 1999-12-22 PT PT99964665T patent/PT1140071E/pt unknown
- 1999-12-22 DK DK05013209.1T patent/DK1588706T3/da active
- 1999-12-22 TR TR2008/05275T patent/TR200805275T2/xx unknown
- 1999-12-22 SI SI9930963T patent/SI1140071T1/sl unknown
- 1999-12-22 CA CA002351357A patent/CA2351357A1/en not_active Abandoned
- 1999-12-22 SK SK913-2001A patent/SK9132001A3/sk unknown
- 1999-12-22 DE DE69935249T patent/DE69935249T2/de not_active Revoked
- 1999-12-22 ES ES99964665T patent/ES2281978T3/es not_active Expired - Lifetime
- 1999-12-22 AT AT99964665T patent/ATE354364T1/de not_active IP Right Cessation
- 1999-12-22 TR TR2008/05741T patent/TR200805741T2/xx unknown
- 1999-12-22 EP EP10010334A patent/EP2298298A3/en not_active Withdrawn
- 1999-12-22 EP EP99964665A patent/EP1140071B1/en not_active Revoked
- 1999-12-22 CA CA2622805A patent/CA2622805C/en not_active Expired - Fee Related
- 1999-12-22 WO PCT/EP1999/010330 patent/WO2000038676A1/en active IP Right Grant
- 1999-12-22 BR BR9916576-7A patent/BR9916576A/pt not_active IP Right Cessation
- 1999-12-22 NZ NZ553010A patent/NZ553010A/en not_active IP Right Cessation
- 1999-12-22 HU HU0104780A patent/HUP0104780A3/hu unknown
- 1999-12-22 CZ CZ20032559A patent/CZ297795B6/cs not_active IP Right Cessation
- 1999-12-22 CZ CZ20012306A patent/CZ293257B6/cs not_active IP Right Cessation
- 1999-12-22 KR KR1020017007996A patent/KR100646716B1/ko not_active IP Right Cessation
- 1999-12-22 SI SI9931064T patent/SI1588706T1/sl unknown
- 1999-12-22 TR TR2006/05471T patent/TR200605471T2/xx unknown
- 1999-12-22 RU RU2001119990/15A patent/RU2271809C2/ru not_active IP Right Cessation
- 1999-12-22 JP JP2000590630A patent/JP2002533390A/ja not_active Withdrawn
- 1999-12-22 TR TR2008/05740T patent/TR200805740T1/xx unknown
- 1999-12-22 ES ES05013209T patent/ES2373556T3/es not_active Expired - Lifetime
- 1999-12-22 NZ NZ511938A patent/NZ511938A/xx not_active IP Right Cessation
- 1999-12-22 PL PL349424A patent/PL199100B1/pl not_active IP Right Cessation
- 1999-12-22 IL IL14323399A patent/IL143233A0/xx not_active IP Right Cessation
2001
- 2001-05-17 IL IL143233A patent/IL143233A/en not_active IP Right Cessation
- 2001-06-22 NO NO20013143A patent/NO328775B1/no not_active IP Right Cessation
2002
- 2002-01-28 HK HK02100661.6A patent/HK1038888B/zh not_active IP Right Cessation
2003
- 2003-12-02 AU AU2003266433A patent/AU2003266433B2/en not_active Ceased
2005
- 2005-08-01 RU RU2005124363/15A patent/RU2361575C2/ru not_active IP Right Cessation
2006
- 2006-07-18 AU AU2006203077A patent/AU2006203077B2/en not_active Expired
- 2006-11-02 IL IL179017A patent/IL179017A0/en unknown
- 2006-11-02 IL IL179015A patent/IL179015A0/en unknown
- 2006-11-02 IL IL179016A patent/IL179016A0/en unknown
2007
- 2007-05-10 CY CY20071100642T patent/CY1106581T1/el unknown
2008
- 2008-11-05 RU RU2008143545/15A patent/RU2008143545A/ru unknown
2009
- 2009-09-24 AU AU2009220022A patent/AU2009220022B2/en not_active Expired
2010
- 2010-01-12 NO NO20100041A patent/NO20100041L/no not_active Application Discontinuation
- 2010-01-18 JP JP2010008140A patent/JP5254258B2/ja not_active Expired - Lifetime
2011
- 2011-12-06 CY CY20111101213T patent/CY1112395T1/el unknown

Also Published As

Publication number	Publication date
JP2002533390A (ja)	2002-10-08
ATE354364T1 (de)	2007-03-15
ES2281978T3 (es)	2007-10-01
CA2622805A1 (en)	2000-07-06
AU2003266433A1 (en)	2004-01-08
JP5254258B2 (ja)	2013-08-07
IL143233A0 (en)	2002-04-21
KR100646716B1 (ko)	2006-11-17
JP2010090169A (ja)	2010-04-22
AU3043000A (en)	2000-07-31
CA2622805C (en)	2011-05-10
EP1588706A3 (en)	2005-12-07
DE69935249T2 (de)	2007-10-31
NZ587909A (en)	2012-05-25
HUP0104780A3 (en)	2002-11-28
PL349424A1 (en)	2002-07-29
IL143233A (en)	2007-07-24
BR9916576A (pt)	2001-10-02
NZ511938A (en)	2004-02-27
CN1636561A (zh)	2005-07-13
ES2373556T3 (es)	2012-02-06
RU2005124363A (ru)	2007-02-10
TR200200764T2 (tr)	2002-07-22
TR200805275T2 (tr)	2008-09-22
AU2003266433B2 (en)	2006-08-10
WO2000038676A1 (en)	2000-07-06
ID29856A (id)	2001-10-18
AU2006203077A1 (en)	2006-08-10
SI1140071T1 (sl)	2007-08-31
PT1140071E (pt)	2007-05-31
IL179017A0 (en)	2007-03-08
DE69935249D1 (de)	2007-04-05
EP1140071B1 (en)	2007-02-21
KR20010089681A (ko)	2001-10-08
EP2298298A3 (en)	2011-05-11
NO20100041L (no)	2001-08-16
AU2009220022A1 (en)	2009-10-15
ATE524176T1 (de)	2011-09-15
EP1588706A2 (en)	2005-10-26
PT1588706E (pt)	2011-12-21
TR200805740T1 (tr)	2010-06-21
TR200805741T2 (tr)	2008-10-21
EP1588706B1 (en)	2011-09-14
TR200605471T2 (tr)	2006-11-21
SI1588706T1 (sl)	2012-01-31
RU2008143545A (ru)	2010-05-10
DK1588706T3 (da)	2012-01-16
CZ20012306A3 (cs)	2001-12-12
CY1112395T1 (el)	2015-12-09
RU2271809C2 (ru)	2006-03-20
AU2006203077B2 (en)	2009-10-08
CY1106581T1 (el)	2012-01-25
EP1140071A1 (en)	2001-10-10
TR200101784T2 (tr)	2001-10-22
IL179015A0 (en)	2007-03-08
NO20013143D0 (no)	2001-06-22
NZ553010A (en)	2008-09-26
CZ293257B6 (cs)	2004-03-17
HK1038888A1 (en)	2002-04-04
NO20013143L (no)	2001-08-16
PL199100B1 (pl)	2008-08-29
RU2361575C2 (ru)	2009-07-20
AU2009220022B2 (en)	2011-11-03
CA2351357A1 (en)	2000-07-06
IL179016A0 (en)	2007-03-08
HUP0104780A2 (hu)	2002-04-29
DK1140071T3 (da)	2007-06-04
HK1038888B (zh)	2007-09-21
CN1304000C (zh)	2007-03-14
TR200605472T1 (tr)	2007-02-21
CN1331590A (zh)	2002-01-16
SK9132001A3 (en)	2002-01-07
CZ297795B6 (cs)	2007-03-28
EP2298298A2 (en)	2011-03-23

Legal Events

Date	Code	Title	Description
2015-07-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO328775B1 (no)	2010-05-10	Komprimerte tabletter omfattende valsartan.
US20100120877A1 (en)	2010-05-13	Additional therapeutic use
JP2024001219A (ja)	2024-01-09	治療活性化合物の医薬組成物
CN104546776B (zh)	2017-08-22	瑞戈非尼片剂药物组合物和制法
AU2004273057B2 (en)	2010-05-27	Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
EP1013273A1 (en)	2000-06-28	Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
TW202206073A (zh)	2022-02-16	用於治療癌症之劑量方案
KR20220038436A (ko)	2022-03-28	약학적 제제
JP2023524151A (ja)	2023-06-08	抗癌剤タンパク質